Article Text

Download PDFPDF
Featured correspondence
Comments on an acute myocardial infarction study
  1. Peter Bramlage1,
  2. Ulrich Tebbe2
  1. 1Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
  2. 2Klinikum Lippe GmbH, Fachbereich Herz-Kreislauf, Detmold, Germany
  1. Correspondence to Professor Dr Ulrich Tebbe, Klinikum Lippe GmbH, Fachbereich Herz-Kreislauf, Röntgenstrasse 18, 32756 Detmold, Germany; ulrich.tebbe{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors' reply: We would like to thank Dr Tormen for his kind appreciation of our work.1 We fully agree with the comments you made and would like to take the opportunity to further clarify some important aspects.

(1) Patients who had contraindications to any of the components of optical medical therapy (OMT), such as hypotension for β-blocker use, thrombocytopenia for antiplatelet use, etc, were excluded from this analysis.2 Further 1-year mortality …

View Full Text


  • Linked articles 205674.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Ethic commission of the Ärztekammer Westfalen-Lippe and the Westfälische Wilhelms Universität Münster.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles